Archives
-
Drug Response Metrics in Cancer: Beyond Viability
2026-09-09
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to separate growth arrest from drug-induced cell death in cancer models. This framework improves interpretation of treatment response by emphasizing response proportions, timing, and orthogonal validation rather than relying on a single viability endpoint.
-
Reelin Signaling Permits Ketamine’s Synaptic Effects
2026-09-09
This PNAS study identifies Reelin–Apoer2–Src family kinase signaling as a permissive pathway for ketamine-induced hippocampal synaptic plasticity and behavioral effects. Its findings suggest that impaired baseline NMDA receptor function, rather than a simple failure of ketamine target engagement, may contribute to nonresponse to ketamine treatment.
-
PPT: Selective ERα Agonist for Reliable Assays
2026-09-08
This scenario-based guide explains how PPT (Propyl Pyrazole Triol), a potent, selective ERα agonist, can improve interpretation of viability, proliferation, and cytotoxicity assays. It covers SKU B6735 handling, controls, ERα-specific readouts, and vendor-selection criteria for reproducible laboratory workflows.
-
EZ Cap™ Cy5 EGFP mRNA: Delivery Workflows
2026-09-08
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) separates mRNA uptake from functional translation through Cy5 and EGFP signals in the same experiment. This practical guide shows how to screen delivery systems, interpret discordant readouts, and connect cellular results with RNA–nanoparticle structure.
-
PPT for ERα Signaling in LUAD
2026-09-07
PPT (Propyl Pyrazole Triol) provides a selective way to perturb ERα signaling while minimizing ERβ-driven interpretation. This guide translates that pharmacology into practical workflows for biomarker validation, female lung adenocarcinoma research, uterotrophic assays, and troubleshooting.
-
Foretinib (GSK1363089) Assay Workflows
2026-09-07
Foretinib (GSK1363089) supports integrated studies of tumor cell growth inhibition, motility, invasion, and metastatic behavior through coordinated Met and VEGFR pathway blockade. This practical guide combines formulation guidance with response metrics that distinguish proliferative arrest from true cell death.
-
ISRIB (trans-isomer) Workflow for ISR Research
2026-09-05
Build sharper ER stress and memory-retention experiments with ISRIB (trans-isomer), a potent PERK inhibitor and functional eIF2B activator. The workflow connects biochemical target engagement to translation, apoptosis, and recognition-memory readouts while separating literature-supported findings from practical optimization choices.
-
LY294002 Workflows for PI3K/Akt Cancer Assays
2026-09-04
Build cleaner PI3K/Akt experiments with LY294002 by combining dose-response design, timed pathway readouts, and viability controls. The workflow translates recent SPP1–macrophage findings in oesophageal squamous cell carcinoma into practical co-culture, apoptosis, autophagy, and tumor-biology assays.
-
Estradiol, ER Signaling, and T-Cell Recovery After Shock
2026-09-04
This study identifies endoplasmic reticulum stress as a mechanistic link between hemorrhagic shock and impaired splenic CD4+ T-lymphocyte function. Its pharmacological experiments indicate that estradiol acts principally through ERα and GPR30 to suppress stress signaling, preserve T-cell proliferation and cytokine production, and reduce splenic injury.
-
CGP 55845 Hydrochloride: GABAB Assay Guide
2026-09-03
CGP 55845 hydrochloride is a potent, selective GABAB receptor antagonist for dissecting presynaptic inhibition and neurotransmitter release modulation in vitro. Its pharmacology supports controlled synaptic transmission research, but it should not be interpreted as a GAT-3 inhibitor or as a clinical treatment.
-
LNP Surface Charge and V-ATPase Drive Nucleic Acid Delivery
2026-09-03
The reference study proposes that lipid nanoparticle tropism depends not only on particle surface charge but also on the V-ATPase activity of the recipient cell. Its in vitro and in vivo experiments connect charge-dependent delivery with endo/lysosomal function, reticuloendothelial-system conditioning, and protein-corona composition.
-
Cycloheximide in Viral Protein Turnover Studies
2026-09-02
Cycloheximide is more than a protein biosynthesis inhibitor: used as a timed perturbation, it can help separate translation-dependent effects from phosphorylation-driven viral trafficking. This guide applies that logic to influenza NEP and vRNP nuclear export while defining practical assay controls and limitations.
-
PPT: A Causal Assay Framework for ERα Research
2026-09-02
PPT (Propyl Pyrazole Triol) enables selective interrogation of ERα biology. This guide connects its receptor pharmacology with the FOXM1–ERα axis in female lung adenocarcinoma and translates that evidence into better assay design.
-
JC-1 Mitochondrial Membrane Potential Assay Kit Guide
2026-09-01
Learn how the JC-1 Mitochondrial Membrane Potential Assay Kit connects ΔΨm measurements with apoptosis research and immunogenic cell death studies. This guide emphasizes mechanism-based controls, interpretation limits, and assay decisions inspired by recent tumor-immunity research.
-
EZ Cap™ EGFP mRNA (5-moUTP) Assay Guide
2026-09-01
A scenario-based guide to using EZ Cap™ EGFP mRNA (5-moUTP), SKU R1016, as an orthogonal reporter in cell viability, proliferation, cytotoxicity, and translation studies. It connects cap structure, 5-moUTP modification, transcript handling, delivery variables, and data interpretation without treating EGFP fluorescence as a substitute for direct viability measurements.